In human asthma, we previously observed that after IL5 inhibition with mepolizumab treatment, the number of intact airway eosinophils was strongly reduced, but the airway deposition of toxic proteins (EPX) and free granules was not significantly attenuated [8]. Here, IL5 is linked to asthma.